Literature DB >> 7628008

Can the immune response control HIV infection?

W E Paul1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628008     DOI: 10.1016/0092-8674(95)90304-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


× No keyword cloud information.
  16 in total

Review 1.  Proving HIV-1 immunity: new tools offer new opportunities.

Authors:  L J Picker
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

3.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 5.  Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm?

Authors:  W C Koff; A M Schultz
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

6.  Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.

Authors:  Fiorenza Cocchi; Anthony L DeVico; Wuyuan Lu; Mikulas Popovic; Olga Latinovic; Mohammad M Sajadi; Robert R Redfield; Mark K Lafferty; Massimo Galli; Alfredo Garzino-Demo; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

7.  Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.

Authors:  I J Caley; M R Betts; D M Irlbeck; N L Davis; R Swanstrom; J A Frelinger; R E Johnston
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract.

Authors:  A L Howell; R D Edkins; S E Rier; G R Yeaman; J E Stern; M W Fanger; C R Wira
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains.

Authors:  B Berkhout; K Verhoef; J L van Wamel; N K Back
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.